{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'stratification level, the number who discontinue treatment and reason(s) for treatment', 'discontinuation, the number that withdrew from the study and reason(s) for study withdrawal, the', 'number on treatment at the date of data cut-off, Durability of Response, and Survival Follow-up', 'phase status.', '13.4.3.', 'Demographic Characteristics', 'Demographic characteristics will be summarized by treatment arm (SVd, Vd, SVdX, and SdX)', 'and overall, and will include sex, race, ethnicity (Hispanic origin), and age at time of consent.', 'For sex, race, ethnicity, the summary statistics will be the number and percentage of patients', 'within each category. For age at time of consent, the mean, standard deviation, median,', 'minimum, and maximum will be provided for each arm and the total sample. No formal', 'hypothesis testing of treatment arm differences will be performed.', '13.4.4.', 'Baseline Characteristics and Medical History', 'Baseline characteristics include height, weight, BSA, ECOG performance status, and smoking', 'history. If the Dubois (Dubois 1916) method for calculating BSA is entered by the site, BSA', 'using the Mosteller (Mosteller 1987) method will be derived using the formula:', 'BSA = Square Root ([Height(cm)xWeight(kg)]/3600)', 'A complete medical history (Section 11.2.2) will be obtained from each patient.', 'Medical history will be summarized by Medical Dictionary for Regulatory Activities (MedDRA)', 'system organ class (SOC) and preferred term. Baseline data will be summarized for each', 'treatment arm using summary statistics; no formal hypothesis testing of treatment arm', 'differences will be performed. Baseline symptoms will be listed only.', '13.5.', 'Efficacy Analysis', '13.5.1.', 'Primary Analysis for PFS', 'The PFS primary endpoint is defined as time from date of randomization until the first date of', 'PD, per IMWG response criteria, or death due to any cause, whichever occurs first. PD for the', 'primary PFS endpoint will be assessed centrally by the IRC (see Section 6.4). Clinical', 'deterioration in the absence of objective M-protein increase is not considered PD. Patients who', 'end study treatment due to clinical deterioration without an objective M-protein increase meeting', 'the IMWG definition of PD will be censored for the PFS analysis. Unless specified otherwise,', 'relapse from CR by positive immunofixation or trace amount (defined as less than 0.5 g/dL) of', 'M-protein is not considered to be PD.', 'The primary analysis of PFS will be performed on the ITT population. The analysis will be', 'repeated for the PP population as a supportive analysis.', 'PFS data will be summarized with KM methodology using 25th, 50th (median), and 75th', 'percentiles with associated 2-sided 95% CIs, as well as percentage of censored observations and', 'proportion of events. Patients who remain progression-free (whether they withdraw from the', 'study or reach their maximum follow-up) will be censored at the date of their last disease', 'assessment. A stratified log-rank test will be used to compare the PFS distributions between', 'treatment arms for the primary efficacy assessment; the strata will be those used for stratified', 'Confidential', 'Page 96', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'randomization. Hazard ratios will be estimated by a stratified Cox proportional hazards model', 'with treatment as the only factor, the strata will be those used for stratified randomization. A', 'non-stratified log-rank test and a Cox proportional hazards model will be used as sensitivity', 'analyses.', 'Additional sensitivity analyses will be performed on the ITT population for the PFS primary', 'endpoint as outlined below:', 'Sensitivity Analysis #1: Events are defined as documented progression as verified by', 'the IRC or death when the patient is closely followed, whichever occurs first. Patients', 'are censored at the date of last disease assessment if no progression is confirmed by', 'the IRC, treatment is discontinued for any reason, new anticancer treatment is started,', 'or death or progression occurs after 2 or more missed visits.', 'Sensitivity Analysis #2: Similar to the primary PFS endpoint analysis but where', 'treatment discontinuation for any reason is counted as an event.', 'Sensitivity Analysis #3: Similar to the primary PFS endpoint analysis but where the', 'initiation of non-study antineoplastic therapy is counted as an event.', 'Sensitivity Analysis #4: Similar to the primary PFS endpoint analysis but where', 'clinical progression is counted as an event in addition to IRC-confirmed PD. Clinical', 'progression is defined as the event when a patient discontinues the treatment with', 'reason of PD but is not classified as PD by IRC.', 'Sensitivity Analysis #5: Similar to the primary PFS endpoint analysis but where the', 'timing of IRC-confirmed PD at an unscheduled visit is changed to the next scheduled', 'visit.', \"Comparison of PFS endpoint by treatment based on Investigator's assessment.\", '13.5.2.', 'Analyses of the Key Secondary Enppoints', 'The following 3 endpoints, which are defined as key secondary endpoints, will be tested at the', 'time of the second PFS IA according to the test sequence below:', \"1. ORR, defined as any response >PR (ie, PR, VGPR, CR, or sCR) based on the IRC's\", 'response outcome assessments, according to the IMWG response criteria', '2. Incidence of any Grade >2 peripheral neuropathy events', \"3. Response rates for responses >VGPR based on the IRC's assessment\", 'The hierarchical testing procedure will be used to maintain the overall Type I error of these', '3 tests at a 1-sided 0.025 level of significance.', 'Statistical significance of the key secondary endpoints will not be claimed until the primary', 'endpoint of PFS has reached significance.', '13.5.2.1. Overall Response Rate', 'The secondary efficacy endpoint of ORR is defined as the proportion of patients who achieve a', \"confirmed PR or better (ie, PR, VGPR, CR, or sCR) based on the IRC's response outcome\", 'assessments, according to the IMWG response criteria, before IRC-confirmed PD or initiating a', 'Confidential', 'Page 97', 'Version 4.0']\n\n###\n\n", "completion": "END"}